Ipamorelin and CJC-1295 Blend Interactions with The Pituitary Gland

Research posits that blending Ipamorelin and CJC-1295 peptides during in vitro research may provide complementary mechanisms. This may potentially include support for overall stimulation of growth hormone secretion from target cells through distinct yet synergistic receptor pathways in mammalian research models.

CJC-1295 is a modified synthetic peptide, structurally related to the endogenously occurring growth hormone-releasing hormone (GHRH). It is modified for increased stability and longer duration of action. Its prolonged duration of action is what makes it stand out compared to other GHRH-analogs.

Ipamorelin, in comparison, is described in research as a pentapeptide and is thought to interact selectively with growth hormone secretagogue receptors (GHS-R). This is a distinct type of receptor compared to the GHRH receptors. Therefore, Ipamorelin is classified as a growth hormone secretagogue (GHS). It stands out from other GHSs as it appears to stimulate growth hormone secretion without potentially providing significant support to other pituitary hormones.

Unfortunately, there is no current research that has investigated the potential of this blend. With this in mind, we will break down the structure, mechanisms, and activity of each of the peptides and discuss their synergistic potential, which should be investigated in future laboratory experiments.

Research

Ipamorelin and CJC-1295 Blend Sequence and Structure

CJC-1295 is structurally derived from the first 29 amino acids of endogenous GHRH. This sequence specifically corresponds to the biologically active N-terminal fragment of the full-length hormone. Researchers such as Jetté et al. highlight that this sequence incorporates several carefully designed amino acid substitutions that may support stability and resistance to enzymatic degradation:⁽¹⁾

• At the second position, there is a substitution with D-alanine, possibly offering protection against rapid cleavage by dipeptidylpeptidase-IV (DPP-IV), a key enzyme involved in the degradation of endogenous GHRH.
• A glutamine residue replaces asparagine at position 8, a modification that may reduce spontaneous chemical rearrangements or hydrolysis of the peptide backbone.
• An alanine is substituted at position 15, which researchers posit may provide some support for overall cellular bioactivity.
• A leucine replaces methionine at position 27. This may potentially minimize oxidation-related degradation.
• An extra lysine residue is added beyond the endogenous sequence, bearing a chemical modification referred to as Nε-3-maleimidopropionic acid (MPA). This modification is also referred to as the Drug Affinity Complex (DAC) and potentially supports covalent binding to albumin, significantly extending the peptide’s half-life and reducing proteolytic degradation.

Ipamorelin, on the other hand, is considerably simpler in structure. The peptide is comprised of only five amino acids—and is thus classified as a pentapeptide. Raun et al. describe its sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH₂.⁽²⁾ This sequence features several synthetic D-form amino acids. These structural peculiarities may contribute significantly to its receptor selectivity and biological activity.

The presence of amino-isobutyric acid (Aib) at the N-terminal end potentially increases resistance to enzymatic breakdown. In contrast, the incorporation of D-amino acids such as D-2-Nal (D-2-naphthylalanine) and D-phenylalanine (D-Phe) may further confer stability and receptor specificity. These unique structural characteristics possibly enable Ipamorelin to selectively interact with GHS-R while minimizing activity on other pituitary hormone receptors.

Ipamorelin and CJC-1295 Blend Action on Pituitary Cells

The somatotroph cells in the anterior pituitary gland are believed to possess distinct receptors capable of recognizing both GHRH and GHS. As highlighted by researchers such as Culhane et al., CJC-1295 appears to interact specifically with GHRH receptors, which are classified as G protein-coupled receptors (GPCRs). ⁽³⁾ Therefore, upon binding, CJC-1295 may activate the GHRH receptor, potentially triggering the coupling of G proteins. This interaction may result in activation of adenylate cyclase (AC), an enzyme catalyzing the conversion of ATP into cyclic adenosine monophosphate (cAMP).

Elevated cAMP levels subsequently activate protein kinase A (PKA), a central kinase that may phosphorylate key downstream proteins. This signaling cascade may potentially culminate in increased transcriptional activation and better-supported release of growth hormone (GH) stored in intracellular vesicles. Due to its prolonged half-life, CJC-1295 is believed to induce a prolonged cAMP-mediated activation, which might result in prolonged GH release in some murine models.

On the other hand, Ipamorelin appears to interact specifically with the growth hormone secretagogue receptor type 1a (GHS-R1a) on somatotroph cells. Raun et al. have highlighted the selectivity of this interaction and have commented that “ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation.”⁽²⁾ This is distinct from the activity of other GHSs, which often also engage with receptors related to ACTH or cortisol.

Further research by Yin et al. suggests that upon binding selectively to GHS-R1a, Ipamorelin may trigger a different intracellular pathway compared to CJC-1295. Specifically, the activated receptor possibly engages a class of G proteins referred to as Gq/11, which in turn may stimulate an enzyme called phospholipase C (PLC). ⁽⁴⁾

Activated PLC then possibly breaks down a specific component of the cell membrane into two signaling molecules, inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ might help release calcium stored inside the cell, thereby increasing calcium levels within the cytoplasm. At the same time, DAG likely activates an enzyme referred to as protein kinase C (PKC).

Together, increased calcium levels and PKC activation may support the release of growth hormone from storage vesicles within the pituitary cells. Thus, although both peptides ultimately target GH secretion, their receptor-specific interactions potentially engage different yet complementary intracellular signaling pathways within pituitary cells.

Ipamorelin and CJC-1295 Blend Action on Growth Hormone Release

As noted, both CJC-1295 and Ipamorelin may interact with different pituitary receptors, which ultimately results in the synthesis of GH from anterior pituitary cells. Several studies have investigated the magnitude of GH release following such an interaction. Notably, research by Teichman et al. has investigated the potential of CJC-1295, revealing that the peptide may upregulate baseline “GH concentrations by 2- to 10-fold”.⁽⁵⁾ Moreover, the researchers commented that the peptide induced the upregulation within 2 hours of exposure, and the elevation lasted for over 140 hours.

The overall amount of GH synthesized was estimated to be about ~758 ng·h/mL in non-stimulated conditions, compared to ~1,370 ng·h/mL in the cells exposed to the continuous action of CJC-1295. On the other hand, Ipamorelin has been reported by researchers such as Gobburu et al. to induce only short-term spikes in GH synthesis. ⁽⁶⁾ These spikes have been suggested to reach up to 26.6 ng/ml, which is more than double the amounts of 5-10 ng/ml that are typically observed in physiological conditions.

Ipamorelin and CJC-1295 Blend Anabolic Potential

The potential increase in growth hormone and other anabolic mediators resulting from CJC-1295 and Ipamorelin may support anabolic signaling in various cell types. Some tissues that might be particularly responsive to this signaling include muscle and bone cells. For instance, preliminary studies examining analogs of CJC-1295 have suggested the peptide may support muscle cell growth in murine models.

Experiments like these may eventually lead to noticeable increases in muscular tissue size and lean muscular tissue mass in mammalian research models. Some research already seems to point in this direction. Specifically, research by Khorram et al. indicated that analogs similar to CJC-1295 might be linked to muscle cell hypertrophy, possibly contributing to gains of approximately 2.77 lbs of lean mass over 16 weeks. ⁽⁷⁾

Similarly, Ipamorelin has been investigated for its possible support for bone cells. Johansen et al. conducted research evaluating whether Ipamorelin might in some way interact with bone mineral content (BMC)—a measure reflecting the total mineral composition of bone tissue. ⁽⁸⁾ In these experiments, researchers recognized the relevant implications of dual-energy X-ray absorptiometry (DXA).

This precise imaging method assesses bone mineral density by analyzing how different tissues absorb X-rays. Their findings indicated a potential significant relevance to studies of BMC observed following exposure to Ipamorelin, suggesting possible relevant actions on bone structure integrity. These researchers commented “that the increases in cortical and total BMC were due to an increased growth of the bones with increased bone dimensions.” Therefore, the Ipamorelin and CJC-1295 Blend may induce a variety of anabolic signals to different tissues. Unfortunately, their combined anabolic potential and possible synergy are yet to be investigated in laboratory settings.

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

1. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.
2. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822.
3. Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol. 2015 Nov 5;6:264. doi: 10.3389/fphar.2015.00264. PMID: 26594176; PMCID: PMC4633518.
4. Yin Y, Li Y, Zhang W. The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int J Mol Sci. 2014 Mar 19;15(3):4837-55. doi: 10.3390/ijms15034837. PMID: 24651458; PMCID: PMC3975427.
5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
6. Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
7. Khorram, O., Laughlin, G. A., & Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479. https://doi.org/10.1210/jcem.82.5.3943
8. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. doi: 10.1054/ghir.1999.9998. PMID: 10373343.